Beigene Ltd (NASDAQ:BGNE) Director Bros. Advisors Lp Baker acquired 1,980,198 shares of Beigene stock in a transaction on Thursday, January 18th. The stock was acquired at an average cost of $101.00 per share, for a total transaction of $199,999,998.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of Beigene Ltd (NASDAQ:BGNE) traded up $5.59 during midday trading on Monday, hitting $118.26. 313,071 shares of the stock were exchanged, compared to its average volume of 326,569. The company has a market capitalization of $5,380.00 and a PE ratio of -90.27. Beigene Ltd has a 52 week low of $31.90 and a 52 week high of $120.00. The company has a current ratio of 9.33, a quick ratio of 9.27 and a debt-to-equity ratio of 0.20.
Beigene (NASDAQ:BGNE) last announced its quarterly earnings results on Monday, November 13th. The company reported $2.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $2.31. The firm had revenue of $220.21 million for the quarter, compared to the consensus estimate of $1.55 million. During the same period in the prior year, the business earned ($1.08) earnings per share. analysts forecast that Beigene Ltd will post -2.04 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Hillhouse Capital Management Ltd. lifted its position in Beigene by 172.6% in the 2nd quarter. Hillhouse Capital Management Ltd. now owns 3,720,726 shares of the company’s stock valued at $167,433,000 after acquiring an additional 2,355,906 shares in the last quarter. Canada Pension Plan Investment Board bought a new stake in Beigene in the 3rd quarter valued at $62,076,000. Janus Henderson Group PLC bought a new stake in Beigene in the 3rd quarter valued at $33,744,000. Alliancebernstein L.P. bought a new stake in Beigene in the 2nd quarter valued at $7,373,000. Finally, Employees Retirement System of Texas bought a new stake in Beigene in the 2nd quarter valued at $2,855,000. 55.32% of the stock is currently owned by institutional investors.
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.